Objective: To investigate the value of pro-gastrin-releasing peptide(Pro-GRP)and neuron-specific enolase (NSE) in the diagnosis and treatment of small cell lung cancer. Methods: Patients who were hospitalized in the Department of Respiratory and Critical Care Medicine of the First Affiliated Hospital of Bengbu Medical College from April 2020 to March 2021 and were first diagnosed with small cell lung cancer (38 patients), non-small cell lung cancer (65 patients) and benign lung disease (51 patients) were included. The clinical general data of the patients were collected and the levels of ProGRP and NSE were detected by electrochemiluminescence to evaluate the clinical diagnosis and treatment value. Results: The levels of serum Pro-GRP and NSE in small cell lung cancer group were significantly higher than those in non-small cell lung cancer group (P＜0.05) and benign lung disease group (P＜0.05). The levels of serum Pro-GRP and NSE in extensive small cell lung cancer group were higher than those in limited small cell lung cancer group (P＜0.05). There was no significant correlation between serum ProGRP level and gender, age and smoking history in patients with small cell lung cancer (P＞0.05). There was no significant correlation between serum NSE level and gender and age history (P＞0.05), but there was a correlation with smoking (P＜0.05). ROC curve analysis showed that the cut-off values of serum Pro-GRP and NSE in the diagnosis of small cell lung cancer were 65.78 pg/mL and 14.84 ng/mL, respectively; the sensitivity, specificity and Youden index of serum Pro-GRP in the diagnosis of small cell lung cancer were 84.21%, 96.1% and 0.803, respectively; the sensitivity, specificity and Youden index of NSE were 68.4%, 96.1% and 0.645, respectively. After 2 cycles of standard chemotherapy, the levels of serum Pro-GRP and NSE in patients with small cell lung cancer after chemotherapy were significantly lower than those before chemotherapy (P＜0.05). Conclusion: Serum Pro-GRP and NSE can be used as tumor markers for the diagnosis and efficacy evaluation of small cell lung cancer.
HONG Lei
,
WANG Ruonan
. Value of pro-gastrin-releasing peptide and neuron-specific enolase in the diagnosis and treatment of small cell lung cancer[J]. Journal of Baotou Medical College, 2024
, 40(8)
: 64
-68
.
DOI: 10.16833/j.cnki.jbmc.2024.08.013
[1] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2020[J].CA Cancer J Clin, 2020, 70(1): 7-30.
[2] Kalemkerian GP, Schneider BJ.Advances in small cell lung cancer[J].Hematol Clin N Am, 2017, 31(1): 143-156.
[3] Ganti AKP, Loo BW, Bassetti M, Blakely C, et al.Small Cell Lung Cancer, Version 2.2022, NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw, 2021, 19(12): 1441-1464.
[4] Carter L, Rothwell DG, Mesquita B, et al.Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer[J].Nat Med, 2017, 23(1): 114-119.
[5] 齐鲁, 丁彦青.肺癌基因异常表达与化疗药物的相关性分析[J].肿瘤防治研究, 2014, 41(5): 405-408.
[6] 高洁, 张伦军, 彭珂, 等.血清肿瘤标志物CEA、CYFRA21-1、SCCAg、NSE、ProGRP在不同病理分型肺癌诊断中的应用价值[J].南方医科大学学报, 2022, 42(6): 886-891.
[7] Mcdonald TJ, Nilsson G, Vagne M, et al.A gastrin releasing peptide from the porcine nonantral gastric tissue[J].Gut, 1978, 19(9): 767-774.
[8] 李佳, 齐军.小细胞肺癌相关肿瘤标志物的研究进展[J].标记免疫分析与临床, 2015, 22(12): 1293-1296.
[9] Ischia J, Patel O, Shulkes A, et al.Gastrin-releasing peptide: different forms, different functions[J].Biofactors, 2009, 35(1): 69-75.
[10] Nash K, Hafeez A, Hou SS.Hospital-acquired renal insufficiency[J].Am J Kidney Dis, 2002, 39(5): 930-936.
[11] 杨静静, 黄猛, 杨佳锦, 等.胃泌素释放肽前体的研究进展[J].国际检验医学杂志, 2013, 34(3): 337-339.
[12] Mauro C, Passerini R, Spaggiari L, et al.New and old biomarkers in the differential diagnosis of lung cancer: pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1[J].Int J Biol Markers, 2019, 34(2): 163-167.
[13] Lee H, Park SD, Kim T, et al.Algorithm using neuron-specific enolase and pro-gastrin-releasing peptide to increase the diagnostic accuracy for small cell lung cancer[J].Ann Lab Med, 2021, 41(3): 339-341.
[14] 李德经, 宁国兰, 柳兆飞, 等.ProGRP和NSE对小细胞肺癌的诊断及疗效评估的价值[J].实用医学杂志, 2016, 32(5): 754-758.
[15] Kim HR, Oh IJ, Shin MG, et al.Plasma proGRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer[J].J Korean Med Sci, 2011, 26(5): 625-630.
[16] 夏国庆, 韩一平.血清神经元特异性烯醇化酶与胃泌素释放肽前体水平评估小细胞肺癌疗效及预后的效果研究[J].中国全科医学, 2019, 22(35): 4322-4326, 4331.
